# CeQur

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cequr

- Industry: Medical Devices & Equipment
- Headquarters: Switzerland
- Website: www.myceqursimplicity.com
- Total disclosed funding: $252M
- Latest round: Series C (Apr 13, 2021)
- Investors on record: 12

## About

Based in Switzerland, CeQur SA focuses on developing innovative insulin delivery solutions, particularly the CeQur Simplicity patch that offers injection-free insulin administration for individuals with diabetes.CeQur SA, founded in 2008 in Switzerland, specializes in diabetes management by providing advanced insulin delivery systems. The company has successfully completed six investment deals, with the most recent funding round occurring on January 7, 2025, raising USD 120.00 mn. Joël Besse, the founder, has a history of engagement in healthcare innovations.CeQur SA specializes in the development and distribution of the CeQur Simplicity, an innovative wearable mealtime insulin patch designed to facilitate injection-free insulin delivery for individuals with diabetes. This product utilizes a small, flexible cannula to administer rapid-acting insulin subcutaneously, significantly reducing the discomfort and inconvenience associated with traditional multiple daily injections. The CeQur Simplicity aims to enhance user experience by providing a simple, discreet, and efficient dosing method that can be employed in various environments without complicated programming or exposed tubing. Targeting markets across North America and Europe, the primary users of this product include adults with type 2 diabetes who require mealtime insulin, along with healthcare professionals who support diabetes management.CeQur SA generates revenue through direct sales of the CeQur Simplicity insulin patch to healthcare providers and patients, as well as potential partnerships with healthcare institutions and diabetes management programs. The transaction structure is primarily B2B, as the company collaborates with clinics and pharmacies to ensure product availability to end users, while also facilitating direct-to-consumer sales through healthcare networks. The CeQur Simplicity is marketed as part of comprehensive diabetes care solutions, potentially bundled with educational resources and support services aimed at improving patient adherence to insulin regimens. Pricing for the CeQur Simplicity is structured to align with market standards for diabetes management products, reflecting its advanced technology and user-friendly design.In January 2025, CeQur SA raised USD 120.00 mn in venture funding to accelerate its business reach in the healthcare platform. The company plans to continue expanding its market presence, focusing on launching new products and entering new geographic regions, including additional markets in Europe and North America. This strategic initiative is set to enhance their offerings in diabetes management, leveraging the recent funding to support these growth objectives.

## Funding rounds

- Series C, Apr 13, 2021, $115M — GMG Capital Partners, Endeavour Vision, Kingdon Capital Management, MDT Advisers, Schroders, Tandem Diabetes Care Inc., Vi Partners, Credit Suisse Entrepreneur Capital, Ypsomed AG
- Series C, Sep 1, 2015, $100M — Endeavour Vision, Schroders, Vi Partners, Arthurian Life Sciences, Woodford Patient Capital Trust
- Series B, Sep 9, 2013, $27M — Endeavour Vision, Schroders, BMC Ventures, Vi Partners
- Series A, Dec 30, 2009, $9.9M — Endeavour Vision, Schroders, BMC Ventures, Vi Partners

## Investors

- Endeavour Vision (https://capitalatlas.ai/funds/endeavour-vision) — Series A, Series B, Series C
- Schroders — Series A, Series B, Series C
- BMC Ventures — Series A, Series B
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A, Series B, Series C
- Arthurian Life Sciences (https://capitalatlas.ai/funds/arthurian-life-sciences) — Series C
- Woodford Patient Capital Trust — Series C
- GMG Capital Partners (https://capitalatlas.ai/funds/gmg-capital-partners) — Series C
- Kingdon Capital Management — Series C
- MDT Advisers — Series C
- Tandem Diabetes Care Inc. — Series C
- Credit Suisse Entrepreneur Capital (https://capitalatlas.ai/funds/credit-suisse-entrepreneur-capital) — Series C
- Ypsomed AG — Series C